Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 8/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948142 | 1.00 | PKN1 (0.38) | PKN1PKN2PTGER4HPGDPARP1 | |
| SCHEMBL23529310 | 0.87 | PKN1 (0.43) | PKN1PKN2PTGER4PARP1JAK2 | |
| SCHEMBL29948273 | 0.87 | PKN1 (0.43) | PKN1PKN2PTGER4PARP1JAK2 | |
| SCHEMBL29948164 | 0.86 | PTGER4 (0.41) | PKN1PKN2PTGER4GRM2 | |
| SCHEMBL23529383 | 0.86 | PKN1 (0.37) | PKN1PKN2PTGER4PARP1SYK | |
| SCHEMBL29948198 | 0.86 | PKN1 (0.37) | PKN1PKN2PTGER4PARP1SYK | |
| SCHEMBL23552398 | 0.86 | PTGER4 (0.41) | PKN1PKN2PTGER4GRM2 | |
| SCHEMBL23529396 | 0.79 | GPR35 (0.35) | PKN1PKN2PARP1 | |
| SCHEMBL29948116 | 0.79 | GPR35 (0.35) | PKN1PKN2PARP1 | |
| SCHEMBL23529303 | 0.79 | PTGER4 (0.41) | PKN1PKN2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | PKN1 2995/4885PKN2 3870/4885PTGER4 2061/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | PKN1 3602/4885PKN2 3792/4885PTGER4 1426/4885 |
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | PKN1 2987/4885PKN2 3800/4885PTGER4 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.